Puro Risk Insights Blog
Our blog is an educational hub for clear and timely insights on the cannabis and hemp industry.
We simplify insurance topics regulatory updates and real world risks into easy to understand content for operators at every stage.
From cultivation to retail we provide practical guidance coverage education and market insights to help you stay compliant protected and informed so you can make smarter and more confident decisions.
ON THE BLOG
CATEGORIES
FEATURED POST
Recent Industry Updates
All Articles
Browse our complete collection of cannabis and hemp insights below. This page brings together all published articles covering policy and regulation, business and economy, legal and justice, industry innovation, and culture and community. Each post is created to educate and inform operators and industry stakeholders by breaking down complex topics into clear, practical insights. Scroll down to explore the full library and stay informed on the issues shaping the industry.
California 10mg Beverage Cap Puts a Growth Lane at Risk
California’s AB 2532 would do more than add a Poison Help line to labels. Its 10 milligram per container cap could redraw the cannabis beverage category fast, which is why operators are fighting it before the April 14 hearing.
DC Cannabis Beverage Bill Creates a Narrow Lane
DC is proposing a tightly regulated lane for THC infused, alcohol free cannabis drinks made through brewery and distillery partnerships. The bigger lesson is not just product innovation. It is how cities may open new formats while keeping sales inside licensed dispensaries and patient only channels.
Texas Medical Cannabis Expansion Tightens the Lane
Texas just added more conditional medical cannabis licenses under the Compassionate Use Program, including GTI and Cresco. The bigger operator lesson is that Texas is widening patient access while keeping the legal lane scarce, controlled, and more valuable.
Louisiana Hospital Cannabis Bill Creates a Narrow Access Lane
Louisiana’s SB 270 would allow certain terminally ill patients to use medical cannabis in hospitals, but only inside a tight policy framework. The real lesson is not just access. It is how clearly the bill separates patient use from hospital staff responsibility.
Federal Hemp Rewrite Could Hit CBD Too
A federal crackdown aimed at intoxicating hemp may also hit many non intoxicating CBD products because of trace THC limits. The bigger lesson is that chemistry details now carry real supply chain and survival risk.
Schedule III Push Survives DOJ Shakeup
The latest reporting says a Justice Department shakeup is not expected to kill the federal push to move cannabis to Schedule III. The real operator question is not just when the rule lands. It is whether lawsuits delay when the tax benefit becomes real.
FDA Opens a Narrow Lane for the CMS CBD Pilot
FDA just opened a very narrow lane for certain oral hemp derived CBD products tied to the new CMS pilot. The move does not open the floodgates, but it does give operators a clearer picture of what the federal government may tolerate right now.
Missouri Track And Trace Bid Signals A Tech Reset
Missouri’s live track and trace bid is bigger than a vendor story. It is a signal that states want cleaner data flow, tighter controls, and better compliance support as legal cannabis markets mature.
CMS CBD Pilot Lawsuit Tests Federal Policy
A federal lawsuit is challenging the CMS hemp derived CBD pilot just as the program begins. The bigger operator lesson is not just about court drama. It is about how fast federal access policy can turn into a documentation and compliance problem.
Texas Smokable Hemp Rules Leave Mail Order Risk Unclear
Texas now blocks in state sales of smokable hemp products, but the bigger issue is what happens next with mail orders and enforcement. Regulators say shipped products must comply too, while attorneys say online orders from out of state still sit in a legal gray area.
Disclaimer: All content on this site is for informational and educational purposes only. We share news, insights, and our own interpretations but do not claim ownership of third-party content, always crediting original sources with links. Views expressed in shared content do not necessarily reflect our own. For accurate and current information, please consult the original publisher.
Ready to review your cannabis coverage?
Call us on (323)905-3396
or growth@cannashield.io

Trulieve and Cronos have each gained roughly 27 percent in 2026 while reporting stronger operating results. The broader signal is that public market attention is increasingly rewarding cash generation, improving margins, liquidity, and measurable revenue growth.